Korean J Urogenit Tract Infect Inflamm.  2014 Oct;9(2):68-73. 10.14777/kjutii.2014.9.2.68.

Recommended Managements for the Herpes Genitalia

• Park HJ

• KMID: 1732617
• DOI: http://doi.org/10.14777/kjutii.2014.9.2.68

Abstract

Herpes simplex virus (HSV) is a member of herpesviridae family viruses, which belong to DNA viruses. HSV-associated diseases are one of the most widespread infection and most genital herpes is caused by HSV type 2 (HSV-2). Treatment of genital herpes is complex. In addition to administration of the standard antiviral medications, an ideal management protocol should also address various aspects of the disease. Oral acyclovir, valacyclovir, and famciclovir are recommended for routine treatment. Long-term suppressive therapy is effective in reducing recurrence rate as well as the risk of transmission to others. However, antiviral drugs cannot cure HSV infection and persist during the lifetime of the host, often in latent form. Management of the sex partner, appropriate counseling, and prevention advice or education are equally important in management of genital herpes. This review provides a summary of several important recent guidelines regarding recommended management for the herpes genitalia.

Keyword

Herpes genitalis; Antiviral agents; Therapy

MeSH Terms

Acyclovir
Antiviral Agents
Counseling
DNA Viruses
Education
Genitalia*
Herpes Genitalis
Herpesviridae
Humans
Recurrence
Simplexvirus
Acyclovir
Antiviral Agents

Reference

1. Fatahzadeh M, Schwartz RA. Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management. J Am Acad Dermatol. 2007; 57:737–63.

2. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006; 296:964–73.

3. Lee CB, Choe HS, Hwang SJ, Lee SJ, Cho YH. Epidemiological characteristics of genital herpes and condyloma acuminata in patients presenting to urologic and gynecologic clinics in Korea. J Infect Chemother. 2011; 17:351–7.

4. Katz AR, Lee MV, Wasserman GM. Sexually transmitted disease (STD) update: a review of the CDC 2010 STD treatment guidelines and epidemiologic trends of common STDs in Hawai'i. Hawaii J Med Public Health. 2012; 71:68–73.

5. Patel R, Alderson S, Geretti A, Nilsen A, Foley E, Lautenschlager S, et al. IUSTI/WHO Europe. European guideline for the management of genital herpes, 2010. Int J STD AIDS. 2011; 22:1–10.

6. Workowski KA, Berman SM. Centers for Disease Control and Prevention. Sexually transmitted disease treatment guidelines, 2010. MMWR Recomm Rep. 2010; 59:20–5.

7. Corey L, Benedetti J, Critchlow C, Mertz G, Douglas J, Fife K, et al. Treatment of primary firstepisode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy. J Antimicrob Chemother. 1983; 12(Suppl B):79–88.

8. Fife KH, Barbarash RA, Rudolph T, Degregorio B, Roth R. Valaciclovir versus acyclovir in the treatment of firstepisode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group. Sex Transm Dis. 1997; 24:481–6.

9. Reyes M, Shaik NS, Graber JM, Nisenbaum R, Wetherall NT, Fukuda K, et al. Task Force on Herpes Simplex Virus Resistance. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med. 2003; 163:76–80.

10. Martin JM, Villalon G, Jorda E. Update on the treatment of genital herpes. Actas Dermosifiliogr. 2009; 100:22–32.

11. Korea Centers for Disease Control and Prevention, Korean Association of Urogenital Tract Infection and Inflammation. Sexually transmitted infections Korean guidelines. Seoul: Korea Centers for Disease Control and Prevention, Korean Association of Urogenital Tract Infection and Inflammation. 2011.

12. Weightman W, Turner T. Allergic contact dermatitis from lignocaine: report of 29 cases and review of the literature. Contact Dermatitis. 1998; 39:265–6.

13. Nilsen AE, Aasen T, Halsos AM, Kinge BR, Tjotta EA, Wikstrom K, et al. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet. 1982; 2:571–3.

14. Sacks SL, Aoki FY, Diaz-Mitoma F, Sellors J, Shafran SD. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. JAMA. 1996; 276:44–9.

15. Spruance SL, Tyring SK, DeGregorio B, Miller C, Beutner K. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Arch Intern Med. 1996; 156:1729–35.

16. Spruance SL, Overall JC Jr, Kern ER, Krueger GG, Pliam V, Miller W. The natural history of recurrent herpes simplex labialis: implications for antiviral therapy. N Engl J Med. 1977; 297:69–75.

17. Mertz GJ, Loveless MO, Levin MJ, Kraus SJ, Fowler SL, Goade D, et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. Arch Intern Med. 1997; 157:343–9.

18. Diaz-Mitoma F, Sibbald RG, Shafran SD, Boon R, Saltzman RL. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group. JAMA. 1998; 280:887–92.

19. Reitano M, Tyring S, Lang W, Thoming C, Worm AM, Borelli S, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group. J Infect Dis. 1998; 178:603–10.

20. Romanowski B, Marina RB, Roberts JN. Valtrex HS230017 Study Group. Patients' preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study. Sex Transm Dis. 2003; 30:226–31.

21. Goldberg LH, Kaufman R, Kurtz TO, Conant MA, Eron LJ, Batenhorst RL, et al. Longterm suppression of recurrent genital herpes with acyclovir. A 5-year benchmark. Acyclovir Study Group. Arch Dermatol. 1993; 129:582–7.

22. Fife KH, Crumpacker CS, Mertz GJ, Hill EL, Boone GS. Recurrence and resistance patterns of herpes simplex virus following cessation of ＞ or = 6 years of chronic suppression with acyclovir. Acyclovir Study Group. J Infect Dis. 1994; 169:1338–41.

23. Mindel A, Faherty A, Carney O, Patou G, Freris M, Williams P. Dosage and safety of longterm suppressive acyclovir therapy for recurrent genital herpes. Lancet. 1988; 1:926–8.

24. Lebrun-Vignes B, Bouzamondo A, Dupuy A, Guillaume JC, Lechat P, Chosidow O. A metaanalysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. J Am Acad Dermatol. 2007; 57:238–46.

25. Geretti AM. Genital herpes. Sex Transm Infect. 2006; 82(Suppl 4):iv31–4.

26. Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, et al. Valacyclovir HSV Transmission Study Group. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004; 350:11–20.

27. Erard V, Wald A, Corey L, Leisenring WM, Boeckh M. Use of longterm suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis. 2007; 196:266–70.

28. Kaliaperumal K. Recent advances in management of genital ulcer disease and anogenital warts. Dermatol Ther. 2008; 21:196–204.

29. Bernstein DI, Aoki FY, Tyring SK, Stanberry LR, St-Pierre C, Shafran SD, et al. GlaxoSmithKline Herpes Vaccine Study Group. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin Infect Dis. 2005; 40:1271–81.

30. Rajcani J, Durmanova V. Developments in herpes simplex virus vaccines: old problems and new challenges. Folia Microbiol (Praha). 2006; 51:67–85.